Ultragenyx Pharmaceutical, Inc. (RARE)
15.43
-0.14
(-0.90%)
USD |
NASDAQ |
Nov 06, 16:00
15.42
-0.01
(-0.06%)
After-Hours: 20:00
Ultragenyx Pharmaceutical Cash from Operations (Quarterly) : -43.00M for Sept. 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -43.00M |
| June 30, 2026 | -97.00M |
| March 31, 2026 | -197.00M |
| December 31, 2025 | -99.83M |
| September 30, 2025 | -91.42M |
| June 30, 2025 | -108.27M |
| March 31, 2025 | -166.48M |
| December 31, 2024 | -79.50M |
| September 30, 2024 | -67.00M |
| June 30, 2024 | -76.96M |
| March 31, 2024 | -190.73M |
| December 31, 2023 | -83.90M |
| September 30, 2023 | -117.87M |
| June 30, 2023 | -116.16M |
| March 31, 2023 | -156.87M |
| December 31, 2022 | -90.34M |
| September 30, 2022 | -95.34M |
| June 30, 2022 | -77.26M |
| March 31, 2022 | -117.52M |
| December 31, 2021 | -54.34M |
| September 30, 2021 | -59.65M |
| June 30, 2021 | -65.36M |
| March 31, 2021 | -159.35M |
| December 31, 2020 | -62.45M |
| September 30, 2020 | -61.97M |
| Date | Value |
|---|---|
| June 30, 2020 | 87.35M |
| March 31, 2020 | -95.15M |
| December 31, 2019 | -72.04M |
| September 30, 2019 | -88.51M |
| June 30, 2019 | -89.06M |
| March 31, 2019 | -95.78M |
| December 31, 2018 | -55.85M |
| September 30, 2018 | -69.16M |
| June 30, 2018 | -76.08M |
| March 31, 2018 | -89.48M |
| December 31, 2017 | -81.82M |
| September 30, 2017 | -61.99M |
| June 30, 2017 | -48.82M |
| March 31, 2017 | -61.20M |
| December 31, 2016 | -47.68M |
| September 30, 2016 | -28.74M |
| June 30, 2016 | -39.66M |
| March 31, 2016 | -44.90M |
| December 31, 2015 | -40.44M |
| September 30, 2015 | -30.60M |
| June 30, 2015 | -17.27M |
| March 31, 2015 | -17.66M |
| December 31, 2014 | -14.74M |
| September 30, 2014 | -11.03M |
| June 30, 2014 | -10.53M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Ionis Pharmaceuticals, Inc. | 565.53M |
| AbbVie, Inc. | 7.606B |
| Krystal Biotech, Inc. | 91.25M |
| BridgeBio Pharma, Inc. | -44.17M |
| Alnylam Pharmaceuticals, Inc. | 340.98M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 58.00M |
| Cash from Financing (Quarterly) | 10.00M |
| Free Cash Flow | -446.77M |
| Free Cash Flow Per Share (Quarterly) | -0.4407 |
| Free Cash Flow to Equity (Quarterly) | -29.00M |
| Free Cash Flow to Firm (Quarterly) | -26.42M |
| Free Cash Flow Yield | -28.63% |